Clinical Trial Update: A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 study of Eloralintide (LY3841136) in participants with obesity or overweight without type 2 diabetes is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Eloralintide (LY3841136)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 3 | Status: RECRUITING